Geographic Atrophy

According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials.

According to the company, the solution slowed the loss of photoreceptors and disease progression as early as six months.

Paul Hahn, MD, PhD, spoke with our team about comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy at the 2023 ASRS annual meeting.

Paul Hahn, MD, PhD, shared insights on research comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy presented at the 2023 ASRS annual meeting.

Apellis Pharmaceuticals, Inc. presented results from the GALE extension study at the 2023 ASRS annual meeting in Seattle. The results indicated that continuous treatment with SYFOVRE (pegcetacoplan injection) for 30 months continued to show increasing beneficial effects.

Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).

Tarek Hassan, MD, spoke with our team about a novel glyco-mimetic nanoparticle for the treatment of geographic atrophy at the 2023 ASRS annual meeting.

Tarek Hassan, MD, spoke with our team about a novel glyco-mimetic nanoparticle, Aviceda AVD-104, being developed for the treatment of geographic atrophy.

At the 2023 ASRS annual meeting in Seattle, Washington, Ursula Schmidt-Erfurth, MD, spoke with our team to share information on the GALE extension study.

Ursula Schmidt-Erfurth, MD, spoke with our team to share information on the GALE extension study at the 2023 ASRS annual meeting.

The companies are partnering to advance a novel therapy with the goal of preserving sight for people living with blinding retinal disease.

In presentations at the ASRS 41st Annual Meeting in Seattle, additional analyses support consistent protection from vision loss.

In presentations at the American Society of Retina Specialists 41st Annual Meeting in Seattle, additional analyses support consistent protection from vision loss.

During presentations at the ASRS 41st Annual Meeting in Seattle, Apellis noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis, and no events were reported in clinical trials.

During presentations at the American Society for Retina Specialists 41st Annual Meeting in Seattle, the company noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis.

Carl Danzig, MD, spoke with our team to share the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy at the 2023 ASRS annual meeting.

At the 2023 ASRS meeting in Seattle, Washington, Carl Danzig, MD, caught up with our team to share the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy.

The American Society of Retina Specialists is hosting its annual meeting this year in Seattle, Washington. Our team caught up with Baruch Kupperman, MD, PHD who is presenting, "Improving vision and dry AMD matching mechanism with the right patient population and stage of disease" to learn more about this topic.

The presenter, Jeffrey S. Heier, MD, Director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston, and an investigator in ARCHER will deliver the data on July 30, 2023.

Belite Bio has completed patient enrollment for a trial evaluating Tinlarebant, which is the first ever treatment for Stargardt Disease.

Cochair Peter J. McDonnell, MD, highlights what this year’s conference will mean for clinicians and addresses the anticipated increased patient volume.

The company plans to share the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.

The American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee has linked Apellis’ pegcetacoplan injection (Syfovre) with a handful of cases of occlusive retinal vasculitis.

According to the ASRS Research and Safety in Therapeutics Committee, ophthalmologists noted instances of intraocular inflammation (IOI) after the initial injection of pegcetacoplan.

The complement system identifies and eliminates pathogens and dying cells, 3 pathways can activate the complement system—classical, lectin, and alternative—and their activation results in similar functions of opsonization, inflammation, and cell lysis.